Find Clinical Trial

Home » Find Clinical Trials » Evaluation of the effects of 3 successive oral dosages (2.5, 5, 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers. A 9 week pilot, open labelled, international multicenter study

Evaluation of the effects of 3 successive oral dosages (2.5, 5, 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers. A 9 week pilot, open labelled, international multicenter study

← Back

Study Phase	Phase 2

Therapeutic Area	Cardiovascular Diseases

Indication	Heart failure

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	IVABRADINE, S016257

Active Substance Code	S016257

Protocol Code	CL2-16257-062

EudraCT Code	2005-000103-34

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.